Drug Trial Radar · NCT05755191
A Study to Assess NEU-411 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
May 13, 2023
Primary completion
Jun 3, 2024
Study completion Jun 3, 2024
Sponsor
- Lead sponsor
- Neuron23 Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), food effect (FE),multiple ascending dose (MAD), drug-drug interaction study, and bioavailability - bio-equivalence study of orally administered NEU-411 in healthy subjects
Conditions
- Healthy
Interventions
NEU-411Drug
Oral Doses
PlaceboDrug
Oral Doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of single dosing, food effect and multiple oral doses of NEU-411 in healthy subjectsTime frame: Up to 7 days of dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.